Clinical Trials Logo

Stage IV Melanoma clinical trials

View clinical trials related to Stage IV Melanoma.

Filter by:

NCT ID: NCT01010984 Completed - Stage IV Melanoma Clinical Trials

LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma

DEBDOX
Start date: September 2009
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if LC beads loaded with Doxorubicin are a safe and effective treatment for melanoma that has spread to the liver.

NCT ID: NCT00871481 Completed - Stage IV Melanoma Clinical Trials

Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma

Start date: February 2009
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial is studying the side effects of giving laboratory-treated T cells and ipilimumab together to see how well they work in treating patients with metastatic melanoma. Treating a patient's T cells in the laboratory may help the T cells kill more tumor cells when they are put back in the body. Monoclonal antibodies, such as ipilimumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving laboratory-treated T cells together with ipilimumab may kill more tumor cells

NCT ID: NCT00726739 Completed - Stage IV Melanoma Clinical Trials

Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma

Start date: June 2008
Phase: Phase 2
Study type: Interventional

RATIONALE: Aldesleukin may stimulate the white blood cells to kill tumor cells. Vaccines may help the body build an effective immune response to kill tumor cells. Giving aldesleukin together with vaccine therapy may kill more tumor cells. It is not yet known whether aldesleukin is more effective with or without vaccine therapy in treating melanoma. PURPOSE: This randomized phase II trial is studying how well aldesleukin works when given with or without vaccine therapy in treating patients with stage IV melanoma.

NCT ID: NCT00669019 Completed - Stage IV Melanoma Clinical Trials

Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

Start date: July 2006
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well saracatinib works in treating patients with stage III or stage IV melanoma that cannot be removed by surgery. Saracatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth

NCT ID: NCT00655655 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors

Start date: December 2004
Phase: Phase 1
Study type: Interventional

RATIONALE: Everolimus and vatalanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving everolimus together with vatalanib may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of everolimus and vatalanib in treating patients with advanced solid tumors.

NCT ID: NCT00651157 Completed - Stage IV Melanoma Clinical Trials

Viral Therapy in Treating Patients With Metastatic Melanoma

Start date: April 2008
Phase: Phase 2
Study type: Interventional

This phase II trial is studying the side effects and how well viral therapy works in treating patients with metastatic melanoma. Viral therapy may be able to kill tumor cells without damaging normal cells.

NCT ID: NCT00553306 Completed - Stage IV Melanoma Clinical Trials

Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma

Start date: September 2007
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Laboratory-treated T cells may be able to kill tumor cells when they are put back into the body. Aldesleukin and cyclophosphamide may stimulate the immune system in different ways and stop tumor cells from growing. Giving laboratory-treated T cells together with aldesleukin after cyclophosphamide may be an effective treatment for melanoma. PURPOSE: This phase I/II trial is studying the side effects of giving laboratory-treated T cells together with aldesleukin after cyclophosphamide and to see how well they work in treating patients with stage IV melanoma.

NCT ID: NCT00498979 Completed - Stage IV Melanoma Clinical Trials

Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers

Start date: May 2007
Phase: Phase 1
Study type: Interventional

RATIONALE: Sodium stibogluconate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Interferon alfa-2b may interfere with the growth of tumor cells and slow the growth of melanoma and other cancers. Drugs used in chemotherapy, such as cisplatin, vinblastine, and dacarbazine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving sodium stibogluconate and interferon alfa-2b together with combination chemotherapy may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of sodium stibogluconate when given together with interferon alfa-2b, cisplatin, vinblastine, and dacarbazine in treating patients with advanced melanoma or other cancer.

NCT ID: NCT00470470 Completed - Stage IV Melanoma Clinical Trials

Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Start date: April 2007
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well imatinib mesylate works in treating patients with stage III or stage IV melanoma that cannot be removed by surgery. Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT00450255 Completed - Stage IV Melanoma Clinical Trials

VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Start date: June 2007
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well VEGF Trap works in treating patients with recurrent stage III or stage IV melanoma that cannot be removed by surgery. Combinations of biological substances in VEGF Trap may be able to carry tumor-killing substances directly to melanoma cells. It may also stop the growth of melanoma by blocking blood flow to the tumor.